Drug Database
OL

olaparib (myChoice CDx)

✓ Approved

Myriad Genetics, Inc. · Companion diagnostic · Companion diagnostic

What is olaparib?

olaparib is a companion diagnostic developed by Myriad Genetics, Inc.. It is approved for therapeutic indications via others.

Drug Profile

Brand NamesmyChoice CDx
CompanyMyriad Genetics, Inc.
Drug ClassCompanion diagnostic
RouteOthers
StatusApproved
Sources: ClinicalTrials.gov, Myriad Genetics, Inc.

Therapeutic Indications

olaparib is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Uterine cancer✓ Approved

Related Research Articles

PubMedJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026-07-17

Combining an αvβ6-Targeted 177Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.

Ganguly Tanushree T, Harris Rebecca E RE, Hausner Sven H SH, Sutcliffe Julie L JL

Pancreatic ductal adenocarcinoma is one of the most lethal malignances worldwide, and there remains an urgent need for more effective and less toxic treatment strategies. Integrin αvβ6 is a cell-surface receptor that is overexpressed in several malignancies, including pancreatic ductal adenocarcinoma, and plays a key role in invasion and metastasis, making it a promising molecular target for the detection and treatment of many cancers. We investigated a molecularly targeted approach that exploits the overexpression of αvβ6 using peptide receptor radionuclide therapy (PRRT) in combination with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib. Methods: We combined the αvβ6-targeted PRRT agent [177Lu]Lu-DOTA-ABM-5G with olaparib, a PARP inhibitor. The combination therapy was evaluated in vitro in αvβ6-positive pancreatic Capan-1 cells by investigating its effect on cell viability, apoptosis induction, cell cycle arrest, and the formation of double-strand breaks. In vivo pharmacokinetic and therapeutic efficacy studies were performed in mice bearing Capan-1 xenograft tumors. Results: In vitro, the [177Lu]Lu-DOTA-ABM-5G was rapidly internalized by αvβ6-positive pancreatic Capan-1 cells; in vivo, it was taken up by Capan-1 xenograft tumors in mice. Combination treatment with [177Lu]Lu-DOTA-ABM-5G and olaparib significantly reduced cell viability (water-soluble tetrazolium salt 1 assay), significantly increased the percentage of cells in the sub-G1 and G2/M phases (cell cycle analysis), and resulted in the greatest number of γ-H2AX foci per cell compared with single-agent treatment. In vivo, the combination treatment delayed tumor growth progression and significantly improved median survival compared with the control and single-agent treatments, with no observed treatment-related adverse events. Conclusion: The combination of αvβ6-targeted PRRT and PARP inhibition enhanced therapeutic efficacy compared with single-agent treatment. These findings warrant further investigation, particularly given the urgent need for improved treatments for pancreatic cancer.

PMID 42463291
Read full article →
PubMedNursing for women's health2026-07-17

Clinical, Ethical, and Practical Implications of Prenatal Genetics for Nurses: Part I.

Bedard-Dureza Catleya C, Morse Brenna B

Prenatal genetic testing provides families with critical information regarding fetal genetic disorders and structural anomalies. As testing options expand, nurses must navigate a range of complex clinical, ethical, and systemic considerations that shape how tests are selected, conducted, and applied to treatment planning. This article discusses prenatal genetic screening and diagnostic modalities and their implications for nursing practice. It is critically important to offer comprehensive pretest and posttest counseling and to address uncertainty surrounding prenatal genetic testing. Provider shortages, time constraints in clinical settings, and evolving policies create barriers to equitable access to genetics care. Nurses play a pivotal role in supporting informed decision-making, promoting health literacy, and addressing equity in prenatal genetic care.

PMID 42463103
Read full article →
PubMedGenetics2026-07-17

Solving the mechanism of Notch activation: a geneticist's perspective.

Greenwald Iva I

Notch mediates cell fate decisions in development and tissue homeostasis and can act as an oncogene or a tumor suppressor depending on the cell context. In my first essay for the GENETICS Perspectives series, "Notch and the Awesome Power of Genetics," I gave my perspective on developments in the field in the 20th century, from the isolation of the eponymous Notch mutations in Drosophila through the elucidation of the mechanism of signal transduction. That essay had a bildungsroman quality about it because the burgeoning of the Notch field and the increasing impact of Caenorhabditis elegans as a model organism coincided with my development as a scientist. But the "awesome power of genetics" was the guiding star of the essay because genetic approaches were largely responsible for identifying the core components of the signaling system and for deducing the novel cleavage mechanism by which Notch transduces signals. In this sequel, I offer my perspective as a geneticist on how the awesome power of genetics continued to have a starring role in the mechanistic discoveries that followed during the first quarter of the 21st century. I aim to show how genetics remains essential both in posing questions and in answering them even as the molecular events associated with activation of Notch signal transduction continue to be elucidated in exquisite structural detail.

PMID 42467462
Read full article →
PubMedAnnals of hematology2026-07-17

Integrated enzymatic and molecular diagnosis of G6PD deficiency: a one-year experience identifying five novel variants.

Duca Lorena L, Fermo Elisa E, Bianchi Paola P, Vercellati Cristina C et al.

Glucose-6-phosphate dehydrogenase (G6PD) deficiency, caused by pathogenic variants in the G6PD gene, is the most common X-linked enzymopathy in the world. The clinical manifestations range from drug-induced hemolytic anemia to neonatal hyperbilirubinemia and chronic hemolysis. The G6PD status needs to be accurately assessed in several clinical settings, including drug prescription, assisted reproductive technologies, and the diagnostic workflow of hemolytic anemia. In this study, the contribution of molecular analysis in the diagnostic workflow of patients with suspected G6PD deficiency was retrospectively evaluated over one year. A total of 340 samples were analyzed for the enzymatic activity of G6PD, including 28 organ donors, 62 pediatric patients, 157 hospitalized patients, and 93 referred from the Genetics, Internal Medicine, Gastroenterology, and Hematology units. Molecular analysis was performed for 52 cases (17 males and 35 females): 37 with reduced enzymatic activity, five with inconclusive results due to recent blood transfusions, and 10 with specific clinical indications. Through molecular testing, eight previously reported and five novel disease-causing variants (c.769 C > T, p.(Arg257Gly); c.488G > T, p.(Gly163Val); c.1124 A > G, p.(Asn375Gly); c.1152G > C p.(Gln384His); c.582 C > G, p.(Asp194Glu)) were identified in 36 patients, along with three common polymorphic variants in 11 other patients. No variants were identified in five patients, consistent with borderline or difficult-to-interpret activity results. Overall, lower G6PD activity was found in 66 of 340 samples (19.4%), while novel variants accounted for 13.5% of cases (5/37). These findings indicate that molecular analysis should be integrated into routine diagnostic workflows for G6PD deficiency and highlight its contribution to expanding the mutational spectrum of the disease.

PMID 42467236
Read full article →
PubMedYi chuan = Hereditas2026-07-17

Integrating cases, enhancing interaction, and promoting learning through assessment: teaching reform and practical outcomes of medical genetics under the OBE concept.

Liang Shi-Qian SQ, Fan Fan F, Hu Yi-Yang YY, Zhao Jun-Long JL et al.

In the new era, the teaching of Medical Genetics requires medical students to not only master solid knowledge, but also possess practical abilities in diagnosing and treating clinical genetic diseases. This paper systematically elaborates on the design and practical exploration of teaching reform in the Medical Genetics course under the Outcome-Based Education (OBE) concept. By constructing a structured teaching system closely aligned with clinical practice, building a teaching model centered on clinical cases, carrying out diverse teaching activities, developing a "boundless classroom", and establishing a multi-dimensional assessment system, we have achieved a deep integration of knowledge transmission and clinical reasoning training. The teaching effectiveness has shown that this model significantly enhances students' case analysis abilities, learning motivation, and innovative capacity. However, the implementation process has also revealed deep-seated challenges in the practical teaching component, such as students facing difficulties in getting started, employing unsystematic methods, producing superficial results, and the imperfection of the evaluation mechanism. Drawing on exemplary domestic teaching cases, this paper proposes that future efforts must synergize two dimensions: "resource support" and "pedagogical design". This involves constructing a tiered, progressive practical ability training chain, improving the faculty development support system, and exploring the use of artificial intelligence to establish process-oriented data platforms and diversified evaluation mechanisms. By putting the OBE concept into practice, we aim to promote a deep transformation of the Medical Genetics course from "knowledge transmission" to "competency development", thereby laying a solid foundation for cultivating outstanding medical talent capable of meeting future medical demands.

PMID 42464729
Read full article →
PubMedNursing for women's health2026-07-17

Clinical, Ethical, and Practical Implications of Prenatal Genetics for Nurses: Part II.

Bedard-Dureza Catleya C, Morse Brenna B

Prenatal genetic testing is integral to routine prenatal care, allowing for early identification of fetal anomalies and informing pregnancy care decisions. Rapidly evolving reproductive health policies have created a complex and contradictory landscape for women's health nurses. Emerging reproductive privacy policies and legal scrutiny of pregnancy loss further complicate clinical practice by introducing risks related to nurse documentation, disclosure, and liability. This article describes how policy changes impact prenatal genetic testing, counseling, and pregnancy management options. The article highlights the critical role of nurses in prenatal genetics care and the need to adopt new counseling strategies, facilitate informed decision-making, and support patients making reproductive care choices in increasingly restrictive environments.

PMID 42463105
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about olaparib